NOV - 9 2005

7.0 510(k) Summary

SUBMITTER: B. Braun Medical Inc.

> 901 Marcon Boulevard Allentown, PA 18109-9341

(610) 596-2367

Contact: Christine Ford

Sr. Regulatory Affairs Analyst

DEVICE NAME: B. Braun Modified Bicarbonate Dialysate

COMMON OR USUAL

NAME: Bicarbonate Dialysate

DEVICE Class II, 21 CFR § 876.5820, Hemodialysis System and

CLASSIFICATION: Accessories (Product Code KPO)

PREDICATE DEVICE: B. Braun Bicarbonate Dialysate

DESCRIPTION: The B. Braun Modified Bicarbonate Dialysate Solutions are

> a family of sterile, non-pyrogenic, bicarbonate dialysate solutions. The solutions will be provided in flexible twochamber bags, with bicarbonate solution in one chamber and electrolyte solution in the other chamber. The chambers are separated by a peel seam. The 5,000 mL ready-to-use solution is obtained by pressing on the small chamber of the bag until the peel seam opens, and then

rocking the bag back and forth to mix the contents.

INTENDED USE: B. Braun Modified Bicarbonate Dialysate is indicated for

hemodialysis use with renal replacement therapy systems

that utilize sterile bicarbonate dialysate

SUBSTANTIAL The B. Braun Modified Bicarbonate Dialysate has a similar **EQUIVALENCE:**

composition range and the same container/closure system

and indications for use as the B. Braun Bicarbonate Dialysate solutions previously cleared under the B. Braun Medical, Inc. 510(k) Premarket Notification K041683.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20050

NOV - 9 2005

Ms. Christine Ford Sr. Regulatory Affairs Analyst B. Braun Medical, Inc. 901 Marcon Blvd. ALLENTOWN PA 18103-9341

Re: K052393

Trade/Device Name: B. Braun Modified Bicarbonate Dialysate

Regulation Number: 21 CFR §876.5820

Regulation Name: Hemodialysis system and accessories

Regulatory Class: II Product Code: KPO Dated: October 13, 2005 Received: October 14, 2005

Dear Ms. Ford:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the <u>Code of Federal Regulations</u>, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

21 CFR 876.xxxx	(Gastroenterology/Renal/Urology)	240-276-0115
21 CFR 884.xxxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 892.xxxx	(Radiology)	240-276-0120
Other		240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Manay C. Brogdon
Nancy C. Brogdon

Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

2.0 Indication	is for Use Stat	tement			-	
			Page	1	_ of	_1
510(k) Number (if l	(nown): <u>K0523</u>	393				
Device Name:	B. Braun Mod	dified Bicarbo	nate Dialysate			
Indications For Use	:					
B. Braun Modified replacement therapy					use wit	th renal
Prescription Use	X	OR	Over-The	-Counter	Use	
(Per 21 CFR 801.10						
(PLEASE DO NOT IF NEEDED)	WRITE BELOV	W THIS LINE	C - CONTINUE	ON ANG	OTHER	. PAGE
Concurrence of CD	RH, Office of De	evice Evaluation	on (ODE)			
	\sqrt{a}	ka cada-				
(Divi	Sion Sign-Off)	y a guon				
Divis	ion of Reproductive, adiological Devices	, Abdominal,	#			
510(k) Number	K0523	<u>93</u>			